Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Drug: fludarabine phosphateDrug: cyclophosphamideBiological: Rituxan (rituximab)Biological: filgrastimDrug: methylprednisoloneOther: immunologic techniqueOther: laboratory biomarker analysisProcedure: autologous hematopoietic stem cell transplantationDrug: DiphenhydramineDrug: Mesna
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00076752
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Lymphoma Trials Office
- Target Recruit Count
- 500
- Registration Number
- NCT00003578
- Locations
- π¨πΏ
Charles University Hospital, Prague (Praha), Czech Republic
π¬π§City Hospital - Birmingham, Birmingham, England, United Kingdom
π³π΄Norwegian Radium Hospital, Oslo, Norway
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
- Conditions
- Childhood Germ Cell TumorTesticular Germ Cell TumorExtragonadal Germ Cell TumorOvarian Cancer
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 45
- Registration Number
- NCT00003852
- Locations
- π«π·
Centre Jean Perrin, Clermont-Ferrand, France
π«π·Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France
π«π·Centre Leon Berard, Lyon, France
Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-01-23
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- London Lung Cancer Group
- Target Recruit Count
- 398
- Registration Number
- NCT00003364
- Locations
- π¬π§
Royal Sussex County Hospital, Brighton, England, United Kingdom
π¬π§Royal Free Hospital, Hampstead, London, England, United Kingdom
π¬π§Cookridge Hospital, Leeds, England, United Kingdom
Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-01-23
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00003541
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-01-22
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- University of Tennessee
- Registration Number
- NCT00003007
- Locations
- πΊπΈ
William F. Bowld Hospital, Memphis, Tennessee, United States
πΊπΈMethodist Healthcare - Hospital of Memphis, Memphis, Tennessee, United States
πΊπΈBaptist Memorial Hospital, Memphis, Tennessee, United States
Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors
- Conditions
- Extragonadal Germ Cell TumorTesticular Germ Cell Tumor
- First Posted Date
- 2004-01-15
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 280
- Registration Number
- NCT00002566
- Locations
- π«π·
Institut Gustave Roussy, Villejuif, France
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic LeukemiaChildhood B Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3154
- Registration Number
- NCT00075725
- Locations
- πΊπΈ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
πΊπΈRush University Medical Center, Chicago, Illinois, United States
πΊπΈChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
- Conditions
- Adult RhabdomyosarcomaEmbryonal Childhood RhabdomyosarcomaEmbryonal-botryoid Childhood RhabdomyosarcomaPreviously Untreated Childhood Rhabdomyosarcoma
- Interventions
- Procedure: conventional surgeryDrug: dactinomycinDrug: vincristine sulfateDrug: cyclophosphamideRadiation: radiation therapy
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 390
- Registration Number
- NCT00075582
- Locations
- πΊπΈ
Driscoll Children's Hospital, Corpus Christi, Texas, United States
πΊπΈWest Virginia University Charleston, Charleston, West Virginia, United States
πΊπΈUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
- Conditions
- Malignant Glioma
- Interventions
- Drug: CarboplatinDrug: CyclophosphamideDrug: Etoposide PhosphateOther: Quality-of-Life AssessmentDrug: Sodium Thiosulfate
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT00075387
- Locations
- πΊπΈ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
πΊπΈOHSU Knight Cancer Institute, Portland, Oregon, United States
πΊπΈUniversity of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.